Accord Healthcare recalled 54,432 bottles of Levothyroxine Sodium Tablets on September 16, 2025. The tablets were found to be subpotent during stability testing. Consumers should stop using the product immediately and seek guidance from healthcare providers.
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
Consumers and healthcare providers should stop using this product immediately. Contact ACCORD HEALTHCARE, INC. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Levothyroxine Sodium Tablets, USP, 88 mcg, packaged in bottles of 90 tablets. The affected lot number is D2300045, with an expiration date of December 31, 2025. These products were distributed nationwide.
The tablets were tested and found to have assay content below the approved specification range. This subpotency can lead to inadequate treatment for patients requiring thyroid hormone replacement.
No specific incidents or injuries have been reported related to this recall. However, the risk of inadequate treatment remains a serious concern.
Stop using the recalled Levothyroxine Sodium Tablets immediately. Contact Accord Healthcare or your healthcare provider for further guidance and potential arrangements for return and refund.
For more information, contact Accord Healthcare at 1-800-XXXX-XXXX or visit their website at www.accordhealthcare.com.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.